Ultragenyx Pharmaceutical share price today
(NASDAQ: RARE)

Name: Ultragenyx Pharmaceutical Share Price Today (NASDAQ: RARE) - Ultragenyx Pharmaceutical Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ultragenyx Pharmaceutical share price is $44.85 & ₹3,879.08 as on 24 Jan 2025, 2.30 'hrs' IST

$44.85

▲

1.91

(4.45%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Ultragenyx Pharmaceutical share price in Dollar and Rupees. Guide to invest in Ultragenyx Pharmaceutical stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ultragenyx Pharmaceutical, along with analyst recommendations, forecasts, and comprehensive financials.

Ultragenyx Pharmaceutical share price movements

Today's Low: $42.77
Today's High: $45.45
$44.85
4.64%
Downside
Day's Volatility :5.9%
Upside
1.32%
52 Weeks Low: $37.02
52 Weeks High: $60.37
$44.85
17.46%
Downside
52 Weeks Volatility :38.68%
Upside
25.71%

Ultragenyx Pharmaceutical Returns

Period	Ultragenyx Pharmaceutical Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-20.22%	-5.5%	0.0%
6 Months	-4.28%	-4.3%	0.0%
1 Year	-5.1%	1.6%	0.0%
3 Years	-37.83%	9.8%	-11.0%

Ultragenyx Pharmaceutical Key Statistics

in dollars & INR

Previous Close	$42.94
Open	$43.05
Today's High	$45.45
Today's Low	$42.77
Market Capitalization	$3.8B
Today's Volume	$796.1K
52 Week High	$60.37
52 Week Low	$37.02
Revenue TTM	$522.7M
EBITDA	$-501.1M
Earnings Per Share (EPS)	$-6.35
Profit Margin	-106.93%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-289.98%

How to invest in Ultragenyx Pharmaceutical Stock (RARE) from India?

It is very easy for Indian residents to invest directly in Ultragenyx Pharmaceutical from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ultragenyx Pharmaceutical stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ultragenyx Pharmaceutical or RARE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ultragenyx Pharmaceutical or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ultragenyx Pharmaceutical shares which would translate to 0.019 fractional shares of Ultragenyx Pharmaceutical as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ultragenyx Pharmaceutical, in just a few clicks!

Returns in Ultragenyx Pharmaceutical for Indian investors in Rupees

Investment Value

₹1,00,000

Ultragenyx Pharmaceutical investment value today

Current value as on today

₹1,03,170

Returns

₹3,170

(+3.17%)

Returns from Ultragenyx Pharmaceutical Stock

₹884 (-0.88%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Ultragenyx Pharmaceutical

-50%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Ultragenyx Pharmaceutical on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -50% less investors are searching Ultragenyx Pharmaceutical in the last 30 days versus the previous period.

Global Institutional Holdings in Ultragenyx Pharmaceutical

Vanguard Group Inc
10.77%
BlackRock Inc
6.31%
Sands Capital Management, LLC
5.54%
Wellington Management Company LLP
4.51%
T. Rowe Price Associates, Inc.
3.32%
Alkeon Capital Management, LLC
3.26%

Analyst Recommendation on Ultragenyx Pharmaceutical

Buy

88%Buy

11%Hold

0%Sell

Based on 27 Wall street analysts offering stock ratings for Ultragenyx Pharmaceutical(by analysts ranked 0 to 5 stars)

Based on 27 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ultragenyx Pharmaceutical

What analysts predicted

Upside of 104.24%

Target:

$91.60

Current:

$44.85

Insights on Ultragenyx Pharmaceutical

Price Movement
In the last 7 days, RARE stock has moved up by 5.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 147.02M → 139.49M (in $), with an average decrease of 5.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -131.59M → -133.51M (in $), with an average decrease of 1.5% per quarter
RARE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 44.0%
RARE vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 131.5%
Price to Sales
ForRARE every $1 of sales, investors are willing to pay $7.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Ultragenyx Pharmaceutical Technicals Summary

Sell

Neutral

Buy

Ultragenyx Pharmaceutical is currently in a neutral trading position according to technical analysis indicators.

Ultragenyx Pharmaceutical Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ultragenyx Pharmaceutical Inc.	-2.01%	-4.28%	-5.1%	-37.83%	-23.81%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ultragenyx Pharmaceutical Inc.	NA	NA	-0.24	-6.18	-2.9	-0.24	NA	3.76
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ultragenyx Pharmaceutical Inc.	Buy	$3.8B	-23.81%	NA	-106.93%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Ultragenyx Pharmaceutical Dividend announcements

Ultragenyx Pharmaceutical Earnings
Ultragenyx Pharmaceutical’s price-to-earnings ratio stands at None
Read More

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Organization	Ultragenyx Pharmaceutical
Employees	1276
CEO	Dr. Emil D. Kakkis M.D., Ph.D.
Industry	Health Technology

Management People of Ultragenyx Pharmaceutical

Name	Title
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, President, CEO & Director
Mr. Howard Horn	Executive VP of Corporate Strategy & CFO
Ms. Karah Herdman Parschauer J.D.	Chief Legal Officer & Executive VP of Corporate Affairs
Mr. John Richard Pinion II	Chief Quality Operations Officer & Executive VP of Translational Sciences
Mr. Erik Harris M.B.A.	Executive VP & Chief Commercial Officer
Mr. Theodore A. Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Ernie W. Meyer	Chief Human Resources Officer & Executive VP
Mr. Thomas R. Kassberg	Chief Business Officer & Executive VP
Mr. Vimal Srivastava	Senior Vice President of Business Development & Alliance Management
Mr. Dennis Karl Huang	Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development

Important FAQs about investing in Ultragenyx Pharmaceutical (RARE) from India :

What is Ultragenyx Pharmaceutical share price today?

Ultragenyx Pharmaceutical share price today stands at $44.85, Open: $43.05 ; Previous Close: $42.94 ; High: $45.45 ; Low: $42.77 ; 52 Week High: $60.37 ; 52 Week Low: $37.02. The stock opens at $43.05, after a previous close of $42.94. The stock reached a daily high of $45.45 and a low of $42.77, with a 52-week high of $60.37 and a 52-week low of $37.02.

Can Indians buy Ultragenyx Pharmaceutical shares?

Yes, Indians can invest in the Ultragenyx Pharmaceutical (RARE) from India.

With INDmoney, you can buy Ultragenyx Pharmaceutical at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ultragenyx Pharmaceutical at zero transaction cost.

How can I buy Ultragenyx Pharmaceutical shares from India?

It is very easy to buy Ultragenyx Pharmaceutical from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ultragenyx Pharmaceutical be purchased?

Yes, you can buy fractional shares of Ultragenyx Pharmaceutical with INDmoney app.

What are the documents required to start investing in Ultragenyx Pharmaceutical stocks?

To start investing in Ultragenyx Pharmaceutical, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.